Advice

in the absence of a submission from the holder of the marketing authorisation:

everolimus (Certican®) is not recommended for use within NHS Scotland.

Indication under review: Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogenic renal transplant.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice135KB (PDF)

Download

Medicine details

Medicine name:
everolimus (Certican)
SMC ID:
1288/17
Indication:
Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogenic renal transplant.
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
13 November 2017